Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510975 | 0.93 | PRMT6 (0.41) | ADORA1 | |
| SCHEMBL4727404 | 0.90 | ADORA1 (0.46) | ADORA1POLBSLC29A1 | |
| SCHEMBL4727394 | 0.90 | ADORA1 (0.46) | ADORA1POLBSLC29A1 | |
| SCHEMBL24102381 | 0.87 | P2RY12 (0.40) | ADORA1 | |
| SCHEMBL18521881 | 0.84 | ADORA1 (0.45) | ADORA1SLC29A1 | |
| SCHEMBL31629565 | 0.83 | POLB (0.49) | ADORA1POLBSLC29A1 | |
| SCHEMBL11683614 | 0.83 | POLB (0.61) | ADORA1POLBSLC29A1 | |
| SCHEMBL19519648 | 0.83 | POLB (0.61) | ADORA1POLBSLC29A1 | |
| SCHEMBL12362206 | 0.83 | POLB (0.61) | ADORA1POLBSLC29A1 | |
| SCHEMBL15143709 | 0.83 | POLB (0.61) | ADORA1POLBSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA1 32/4885POLB 354/4885SLC29A1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.